Stock VBV VBI VACCINES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company VBI Vaccines Inc. Toronto S.E.

Equities

VBV

CA91822J1030

Biotechnology & Medical Research

Delayed Toronto S.E.
Other stock markets
 05:39:59 2018-03-23 pm EDT 		5-day change 1st Jan Change
4.82 CAD -5.12% Intraday chart for VBI Vaccines Inc. -7.66% -10.58%
May. 29 VBI Vaccines Inc. Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients CI
May. 22 VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients CI

Business Summary

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.

Sales per Business

USD in Million2022Weight2023Weight Delta
License
41.4 %
- - 4 41.4 % -
Vaccines
35.8 %
1 86.0 % 3 35.8 % +233.73%
Research & Development Service
22.8 %
0 14.0 % 2 22.8 % +1,210.60%

Sales per region

USD in Million2022Weight2023Weight Delta
China/Hong Kong
64.3 %
0 6.1 % 6 64.3 % +8,362.12%
United States
21.3 %
1 64.2 % 2 21.3 % +165.47%
Europe
12.5 %
0 0.6 % 1 12.5 % +17,983.33%
Israel
1.9 %
0 29.1 % 0 1.9 % -46.98%

Managers

Managers TitleAgeSince
Jeff Baxter CEO
 Chief Executive Officer 62 16-04-30
Nell Beattie DFI
 Director of Finance/CFO 36 15-07-08
David Anderson CTO
 Chief Tech/Sci/R&D Officer 54 16-05-05
Francisco Diaz-Mitoma CTO
 Chief Tech/Sci/R&D Officer 69 16-01-31
Nicole Anderson IRC
 Investor Relations Contact - 17-09-30
Athena Kartsaklis PRN
 Corporate Officer/Principal 59 17-05-22
Misha Nossov PRN
 Corporate Officer/Principal - 10-04-30
John Dillman PRN
 Corporate Officer/Principal 56 22-07-11
Avi Mazaltov PRN
 Corporate Officer/Principal 62 17-03-29
T. Buckley PRN
 Corporate Officer/Principal 48 00-12-31

Members of the board

Members of the board TitleAgeSince
Vaughn Himes BRD
 Director/Board Member 63 23-04-23
Steven Gillis CHM
 Chairman 71 04-12-31
Jeff Baxter CEO
 Chief Executive Officer 62 16-04-30
Damian Braga BRD
 Director/Board Member 68 20-03-08
Michel de Wilde BRD
 Director/Board Member 74 16-04-30
Blaine McKee BRD
 Director/Board Member 59 19-01-10
Nell Beattie DFI
 Director of Finance/CFO 36 15-07-08
Joanne Cordeiro BRD
 Director/Board Member 66 19-04-14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 28,682,275 25,479,871 ( 88.83 %) 0 88.83 %

Shareholders

NameEquities%Valuation
Brii Biosciences Ltd.
6.606 %
1,894,685 6.606 % 1 M $
Perceptive Advisors LLC
4.399 %
1,261,710 4.399 % 832 729 $
Perceptive Advisors LLC
4.399 %
1,261,710 4.399 % 832 729 $
ARCH Venture Partners LLC
3.637 %
1,043,291 3.637 % 688 572 $
Alyeska Investment Group LP
2.184 %
626,436 2.184 % 413 448 $
Vanguard Group, Inc. (Subfiler)
0.6430 %
184,436 0.6430 % 121 728 $
Geode Capital Management LLC
0.5007 %
143,621 0.5007 % 94 790 $
BlackRock Institutional Trust Co. NA
0.3786 %
108,591 0.3786 % 71 670 $
Cambridge Investment Research, Inc.
0.2931 %
84,082 0.2931 % 55 494 $
Renaissance Technologies LLC
0.1999 %
57,341 0.1999 % 37 845 $

Company contact information

VBI Vaccines, Inc.

160 2nd Street Floor 3

02142, Cambridge

+

http://www.vbivaccines.com
address VBI Vaccines Inc.(VBV)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Ratings for VBI Vaccines Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.787 USD
Average target price
5 USD
Spread / Average Target
+535.32%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+22.10% 46.55B
LONZA GROUP AG Stock Lonza Group AG
+46.45% 41.84B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.12% 40.84B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+36.10% 32.95B
CELLTRION, INC. Stock Celltrion, Inc.
-6.30% 28.27B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+18.71% 27.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+46.15% 14.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+44.52% 13.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.19% 12.18B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VBIV Stock
  4. VBV Stock
  5. Company VBI Vaccines Inc.